| 英文别名: |
3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one;Semaxanib (SU5416);SU 5416;3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one;Semaxanib;Semaxinib;1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one;SU-5416;SU5416;Semoxind;TSU 16;VEGF Receptor 2 Kinase Inhibitor III;(Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one;VEGFR2 Kinase Inhibitor III;71IA9S35AJ;3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole;(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one;3-;BRD-K63504947-001-14-7;(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one;NCGC00094381-02;HMS3268J13;NCGC00094381-05;BRD-K63504947-001-15-4;BCP06068;CCG-205186;NCGC00094381-06;SEMAXANIB [USAN];s2845;NCGC00094381-19;BRD-K63504947-001-16-2;Semaxnib;3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone;BRD-K63504947-001-05-5;3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole;SDCCGSBI-0051079.P007;methylene]-2H-indol-2-one;3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one;2H-Indol-2-one, 3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene)- 1,3-dihydro-, (Z)-;SEMAXANIB [MART.];3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one;(3Z)-3-[(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE]-2,3-DIHYDRO-1H-INDOL-2-ONE;BDBM497339;HMS3263M22;AC-35250;MFCD01940922;SDCCGSBI-0051079.P003;H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-;(3Z)-3-((3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONE;HMS3229O13;Romiplate;HMS3677H10;194413-58-6;Tox21_111271_1;NSC-696819;NCGC00094381-01;CHEBI:91083;BDBM4810;(E)-3-((3,5-Dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one;Semaxanib [USAN:INN];204005-46-9;SCHEMBL8190;3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one;SR-01000076044;NCGC00094381-03;CHEMBL276711;HSCI1_000303;Semaxanib (SU5416)?;SCHEMBL19571;SEMAXANIB [WHO-DD];CAS-204005-46-9;DB06436;1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl);Semaxanib; SU5416;MLS001074896;SR-01000076044-2;Semaxanib (USAN/INN);2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-;MLS001332519;HMS3648O12;DTXSID1041132;SIBNPBQTUXWRMZ-ZSOIEALJSA-N;J-013281;Tox21 111271;2H-INDOL-2-ONE, 3-(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLENE)- 1,3-DIHYDRO-,(Z)-;DTXSID801025708;Semaxanib [INN];3-[(3,5-Dimethyl-2H-pyrrol-2-ylidene)methyl]-1H-indol-2-ol;(Z)-SU 5416;AKOS040744647;NSC696819;EU-0101110;2H-Indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-;S 8442;Sugen 5416;NSC 696819;3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one;MLS001332520;AKOS015994557;3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinon;Lopac0_001110;(3E)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-2,3-dihydro-1H-indol-2-one;(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]indolin-2-one;LP01110;3-[(3,5-Dimethyl-1H-... |